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Abstract
We analyzed the species distribution of Candida blood isolates (CBIs), prospectively collected between 2004 and 2009 within FUNGINOS,
and compared their antifungal susceptibility according to clinical breakpoints deﬁned by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) in 2013, and the Clinical and Laboratory Standards Institute (CLSI) in 2008 (old CLSI breakpoints) and 2012
(new CLSI breakpoints). CBIs were tested for susceptiblity to ﬂuconazole, voriconazole and caspofungin by microtitre broth dilution
(Sensititre YeastOneTM test panel). Of 1090 CBIs, 675 (61.9%) were C. albicans, 191 (17.5%) C. glabrata, 64 (5.9%) C. tropicalis, 59 (5.4%)
C. parapsilosis, 33 (3%) C. dubliniensis, 22 (2%) C. krusei and 46 (4.2%) rare Candida species. Independently of the breakpoints applied,
C. albicans was almost uniformly (>98%) susceptible to all three antifungal agents. In contrast, the proportions of ﬂuconazole- and
voriconazole-susceptible C. tropicalis and F-susceptible C. parapsilosis were lower according to EUCAST/new CLSI breakpoints than to the
old CLSI breakpoints. For caspofungin, non-susceptibility occurred mainly in C. krusei (63.3%) and C. glabrata (9.4%). Nine isolates (ﬁve
C. tropicalis, three C. albicans and one C. parapsilosis) were cross-resistant to azoles according to EUCAST breakpoints, compared with three
isolates (two C. albicans and one C. tropicalis) according to new and two (2 C. albicans) according to old CLSI breakpoints. Four species
(C. albicans, C. glabrata, C. tropicalis and C. parapsilosis) represented >90% of all CBIs. In vitro resistance to ﬂuconazole, voriconazole and
caspofungin was rare among C. albicans, but an increase of non-susceptibile isolates was observed among C. tropicalis/C. parapsilosis for the
azoles and C. glabrata/C. krusei for caspofungin according to EUCAST and new CLSI breakpoints compared with old CLSI breakpoints.
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Introduction
Candida species are among the top ten pathogens causing
bloodstream infections [1]. Candidaemia is an invasive fungal
infection associated with substantial morbidity, mortality and
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healthcare costs [2]. Changes in species distribution and a shift
to more resistant isolates are increasingly described [3–5].
There have been signiﬁcant differences in clinical breakpoint
values deﬁned by the Antifungal Susceptibility Testing Sub-
committee of the Clinical and Laboratory Standards Institute
(CLSI) in the USA and by the European Committee on
Antimicrobial Susceptibility Testing (AFST-EUCAST) in Eur-
ope. In recent years a harmonization of these breakpoints as
well as the deﬁnition of species-speciﬁc breakpoints has been
achieved and the breakpoints have been lowered in order to
better detect low level resistance [6–8].
The goal of our study was to analyse the species distribution
of Candida blood isolates (CBIs) prospectively collected in the
hospitals of the Fungal Infection Network of Switzerland
(FUNGINOS) and to determine antifungal susceptibility to
ﬂuconazole, voriconazole and caspofungin according to the
new species-speciﬁc clinical breakpoints deﬁned by the
EUCAST in Europe (in 2013) as well as by the CLSI (in 2008
[old CLSI breakpoints] and 2012 [new CLSI breakpoints]) in
the USA. We also aimed to evaluate the frequency of cross-
and multiresistant isolates.
Material and Methods
Participating hospitals and microbiology laboratories
All Swiss university hospitals (n = 7) and a representative
sample of university-afﬁliated tertiary care centres (n = 10) of
FUNGINOS prospectively collected CBIs between 1 January
2004 and 31 December 2009.
Sixteen microbiology laboratories were afﬁliated with the
17 participating hospitals. All laboratories used automated
blood culture systems [11 Bactec (Becton Dickinson, Sparks,
MD, USA) and ﬁve BacT/Alert (bioMerieux, Durham, NC,
USA)]. The CBIs of each participating centre were sent to the
FUNGINOS mycology reference laboratory in Lausanne.
Species identiﬁcation, antifungal susceptibility testing and
interpretation
In the mycology reference laboratory, the CBI were identiﬁed
by recognized standard laboratory techniques [9] and antifun-
gal susceptibility testing for ﬂuconazole, voriconazole and
caspofungin was performed using the microtitre broth dilution
method with the Sensititre YeastOneTM test panel (version
4.0 from 2004 to 2007; version 7.0 from 2007 to 2009).
Interpretation of susceptibility was performed by applying
the clinical interpretive breakpoints deﬁned by the CLSI in
2008 (old CLSI breakpoints≫) [10,11] and 2012 (new
CLSI breakpoints≫) [12] as well as EUCAST in March 2013
(EUCAST breakpoints≫; http://www.eucast.org/clini-
cal_breakpoints/; version 6.1). EUCAST has not yet deﬁned
clinical breakpoints for caspofungin.
The proportions of susceptible vs. non-susceptible or
resistant CBIs were calculated and compared according to
EUCAST and CLSI breakpoints.
Deﬁnitions
Susceptibility and non-susceptibility. A CBI was considered
susceptible when the minimal inhibitory concentration (MIC)
was at or below the breakpoint deﬁned by EUCAST or CLSI.
Non-susceptibility of a CBI was deﬁned when its MIC was
higher than the breakpoints deﬁned by EUCAST/CLSI and
includes both dose-dependent susceptible, intermediate and
resistant isolates.
Cross-resistance. Cross- resistance was deﬁned as resistance to
two antifungals of the same drug class. We evaluated
cross-resistance to azoles, deﬁned as resistance to the two
azoles tested (ﬂuconazole and voriconazole).
Multi-resistance. Multi-resistance was deﬁned as resistance to
two antifungal drug classes, namely the azoles (ﬂuconazole and
voriconazole) and echinocandin tested (caspofungin).
Data collection and analysis
For data entry and analysis Microsoft Excel (Microsoft
Corporation, Redmond, WA, USA) and its tools were used.
Results
Species distribution
Within the 6 years of the study, a total of 1090 CBIs
underwent central re-identiﬁcation and susceptibility testing.
The most frequently isolated species were C. albicans (675;
61.9%) followed by C. glabrata (191; 17.5%), C. tropicalis (64;
5.9%) and C. parapsilosis (59; 5.4%), accounting for 90.7% of the
total number of isolates. The remaining 9.3% of the species
consisted of C. dubliniensis (33; 3%), C. krusei (22; 2%), C. lusi-
taniae C (12; 1.1%), C. guilliermondii (9; 0.8%), C. kefyr (8; 0.7%),
C. pelliculosa (6; 0.6%), C. famata (4; 0.4%), C. norvegensis (3;
0.3%), C. inconspicua (2; 0.2%) and C. rugosa (2; 0.2%).
Antifungal susceptibility
We applied interpretive breakpoints deﬁned by EUCAST and
CLSI [6–8] [http://www.eucast.org/clinical_breakpoints/; ver-
sion 6.1], summarized in Table 1. The percentage of suscep-
tibility of the different Candida species to ﬂuconazole,
voriconazole and caspofungin is shown in Fig. 1(a–c).
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 698–705
CMI Orasch et al. Susceptibility of swiss candidemia isolates 699
Fluconazole. Non-susceptibility was found in 13 (1.6%) vs.
three (0.4%) of all C. albicans isolates when applying EUCAST/
new CLSI breakpoints vs. the old CLSI breakpoint. Likewise,
seven (11%) C. tropicalis isolates were non-susceptible when
applying EUCAST/new CLSI breakpoints as opposed to two
(3%) when applying the old CLSI breakpoints, and nine (15.3%)
C. parapsilosis were non-susceptible according to EUCAST/
new CLSI bp vs. two (3.4%) according to old CLSI breakpoints.
Ninety-two (48.2%) of all C. glabrata isolates were non-
susceptible when the old CLSI breakpoint was applied, mostly
dose-dependent susceptible (76; 39.8%), whereas all 191
isolates were by deﬁnition non-susceptible according to the
new CLSI breakpoint. EUCAST has not deﬁned a breakpoint
for C. glabrata because of insufﬁcient evidence.
Voriconazole. Non-susceptibility was found in four (0.6%) vs.
three (0.4%) of all C. albicans isolates according to the
EUCAST/new CLSI breakpoints vs. the old CLSI breakpoint
and in 14 (22%) vs. none of the C. tropicalis isolates. For
C. parapsilosis, only one (1.7%) isolate was non-susceptible
according to the EUCAST/new CLSI breakpoints vs. none
according to the old CLSI breakpoint. Seven (3.7%) of all
C. glabrata isolates tested non-susceptible according to the old
CLSI breakpoint, whereas no breakpoint was deﬁned by CLSI
2012 and EUCAST due to insufﬁcient evidence. Four (18.2%)
C. krusei isolates tested non-susceptible when applying the new
CLSI breakpoint, while only one (4.5%) was non-susceptible
when applying the old CLSI breakpoint. EUCAST has not
deﬁned a breakpoint for voriconazole in C. krusei because
there is insufﬁcient evidence that this species is a good target
for therapy with this drug.
Caspofungin. Due to signiﬁcant inter-laboratory variations in
MIC ranges, EUCAST has not deﬁned breakpoints for
caspofungin yet, anidulafungin and micafungin being the echi-
nocandins for which a breakpoint was recently established.
According to the new CLSI breakpoint, one (0.1%) of all the
C. albicans isolates was found non-susceptible vs. none when
the old CLSI breakpoint was applied. Two (3%) vs. one (1.6%)
of the C. tropicalis isolates and none vs. none of the
C. parapsilosis isolates were non-susceptible according to the
new CLSI vs. the old CLSI breakpoint, in contrast to 18 (9.4%)
vs. none of all C. glabrata isolates. Fourteen (63.3%) C. krusei
isolates tested non-susceptible when applying the new CLSI
breakpoint vs. none when applying the old CLSI breakpoint.
Cross-resistance to azoles. A resistance to the two azoles
(ﬂuconazole and voriconazole) tested was found in nine (0.8%)
of all CBIs (ﬁve C. tropicalis, three C. albicans and one
C. parapsilosis) when applying the EUCAST breakpoints vs.
three isolates (two C. albicans and one C. tropicalis) according
to new CLSI breakpoints. Only two isolates (two C. albicans)
were cross-resistant according to the old CLSI breakpoints
(Table 2).
Multi-resistance. One C. tropicalis isolate was resistant to
ﬂuconazole and voriconazole according to the EUCAST and
new CLSI breakpoints and, despite the fact that a breakpoint
for caspofungin has not yet been established by EUCAST, we
considered this isolate with the very high MIC of 16 mg/L for
caspofungin as resistant. No CBI was multiresistant when old
CLSI breakpoints were applied (Table 2).
Discussion
Candidaemia is one of the most common invasive fungal
infections in the hospital setting and associated with a high
attributable mortality [2,13]. An epidemiological shift from
C. albicans to other, usually more resistant Candida species has
been observed in the past years [14,15]. The in vitro activity of
antifungal agents against different species of Candida is not
TABLE 1. Antifungal clinical breakpoints (in mg/L)
Fluconazole
Candida species
Old CLSI bp
(2008)
New CLSI bp
(2012)
EUCAST bp
2013
S SDD R S SDD R S R
C. albicans ≤8 16–32 ≥64 ≤2 4 ≥8 ≤2 >4
C. tropicalis ≤8 16–32 ≥64 ≤2 4 ≥8 ≤2 >4
C. parapsilosis ≤8 16–32 ≥64 ≤2 4 ≥8 ≤2 >4
C. glabrata ≤8 16–32 ≥64 ≤32 ≥64 ≤0.002 >32
C. krusei R R R R R R – –
Voriconazole
Candida
species
Old CLSI bp
(2008) New CLSI bp (2012)
EUCAST bp
2013
S SDD R S I R S R
C. albicans ≤1 2 ≥4 ≤0.12 0.25–0.50 ≥1 ≤0.12 >0.12
C. tropicalis ≤1 2 ≥4 ≤0.12 0.25–0.50 ≥1 ≤0.12 >0.12
C. parapsilosis ≤1 2 ≥4 ≤0.12 0.25–0.50 ≥1 ≤0.12 >0.12
C. glabrata ≤1 2 ≥4 IE IE IE IE IE
C. krusei ≤1 2 ≥4 ≤0.5 1 ≥2 IE IE
Caspofungin
Candida species
Old CLSI bp
(2008) New CLSI bp (2012)
S R S I R
C. albicans ≤2 >2 ≤0.25 0.5 ≥1
C. tropicalis ≤2 >2 ≤0.25 0.5 ≥1
C. parapsilosis ≤2 >2 ≤2 4 ≥8
C. glabrata ≤2 >2 ≤0.125 0.25 ≥0.5
C. krusei ≤2 >2 ≤0.25 0.5 ≥1
bp, breakpoint; CLSI, Clinical and Laboratory Standards Institute; EUCAST,
European Committee on Antimicrobial Susceptibility Testing; I, intermediate; IE,
insufﬁcient evidence; R, resistant; SDD, dose-dependent susceptible; S, susceptible;
–, antifungal susceptibility testing not recommended.
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FIG. 1. (a) Susceptibility of Candida blood isolates to ﬂuconazole according to breakpoints applied. *No susceptible isolates (MIC ≤0.002 mg/L); 175
isolates with an MIC of 0.25–32 mg/L; 16 resistant isolates (MIC >32 mg/L). ‡CLSI breakpoints deﬁne dose-dependent susceptibility (MIC ≤32 mg/L)
and resistance (MIC ≥64 mg/L), thus per deﬁnition there are no susceptible isolates of C. glabrata. (b) Susceptibility of Candida blood isolates to
voriconazole according to breakpoints applied. *No CLSI and EUCAST breakpoints due to insufﬁcient evidence. (c) Susceptibility of Candida blood
isolates to caspofungin according to breakpoints applied. bp, breakpoint; CLSI, Clinical and Laboratory Standards Institute; EUCAST, European
Committee on Antimicrobial Susceptibility Testing.
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uniform and each of them has a speciﬁc antifungal susceptibility
proﬁle. Both CLSI and EUCAST established clinical break-
points for antifungals against Candida species, on the basis of
MIC distributions, pharmacokinetics, pharmacodynamics, epi-
demiological cut-off values (ECOFF) and clinical outcomes
depending on MIC values, for the ﬁve most common Candida
species, C. albicans, C. glabrata, C. tropicalis, C. parapsilosis and
C. krusei [16–19]. In the past 3 years, CLSI adjusted their
susceptibility breakpoints for ﬂuconazole by lowering them to
the same MIC values as EUCAST for C. albicans, C. parapsilosis
and C. tropicalis. The objectives were to detect emerging
resistance among the most common Candida species and to
harmonize the breakpoints with those of EUCAST [6]. CLSI
still deﬁnes breakpoints for ﬂuconazole in C. glabrata as well as
voriconazole in C. krusei [7,12] while EUCAST did not because
of insufﬁcient evidence. However, applying the CLSI break-
points, there are by deﬁnition only dose-dependent suscepti-
ble/resistant and no susceptible C. glabrata isolates anymore.
The single breakpoint for all three echinocandins and all
Candida species proposed by the CLSI in 2008 (susceptible:
≤2 mg/L) has been revised and species-speciﬁc, lower break-
points deﬁned in order to identify isolates with resistance
mechanisms, especially Candida strains with FKS mutations,
possibly leading to treatment failures [8]. EUCAST recently
deﬁned clinical breakpoints for anidulafungin and micafungin
(http://www.eucast.org/clinical_s/).
In Switzerland, the majority of CBIs collected between 2004
and 2009 were C. albicans (61.9%), followed by C. glabrata
(17.5%). The proportion of C. albicans is comparable with data
from Denmark [20], but is higher than in countries [21] such as
Spain (49%) [22], the UK (52%) [23], South Korea (38%) [24],
Mexico (32%) [25] and the USA (45%) [26]. A trend towards
more non-albicans Candida species in Switzerland was
observed transiently in 2006 but it did not persist in the
following years. This is in sharp contrast to the shift towards
more resistant species described in several European countries
and in the USA [27,28]. Overall, C. albicans remained the most
common cause of candidaemia in Switzerland and was almost
uniformly (>98%) susceptible to all three antifungal agents
tested, independently of the breakpoints applied. In contrast,
the proportions of ﬂuconazole-susceptible C. tropicalis and
C. parapsilosis were lower according to the EUCAST and new
CLSI vs. old CLSI breakpoints. A decrease in ﬂuconazole-
susceptibility in candidaemia isolates in general has been
described in Denmark, independently of the breakpoints
applied [28]. Yet, the proportion of ﬂuconazole resistance
among C. tropicalis and C. parapsilosis in the Danish study was
lower than that in the present study (6.7% vs. 11% and 6% vs.
15%) when applying the EUCAST breakpoints. Differences in
the use of ﬂuconazole, especially as prophylaxis, between
countries or institutions might account for these differences in
susceptibility rates, as well as the possible spreading of
resistant clones.
Regarding voriconazole, applying the EUCAST and new
CLSI breakpoints did not change the proportions of non-
susceptibility for C. albicans, which remained below 1% inde-
pendently of the breakpoint applied. However, the application
of the EUCAST and new CLSI breakpoints for voriconazole
increased the proportion of non-susceptible C. tropicalis
isolates (22%) vs. the old CLSI breakpoint (0%). This propor-
tion of voriconazole susceptibility in Switzerland is comparable
to that reported from the USA (<1% resistance) [26] when
applying the old CLSI breakpoint and our level of non-suscep-
tibility is lower compared with data from Austria and Germany
(applying the new CLSI breakpoint) describing 38% of
non-susceptibility to voriconazole [29]. However, compared
with a Danish study reporting 6% of C. tropicalis isolates as
non-susceptible to voriconazole, we observed a higher rate of
non-susceptibility in C. tropicalis isolates when applying the
EUCAST breakpoint [28]. Besides spreading of resistant
clones, as mentioned above for ﬂuconazole, differences in
availability and utilization policies of voriconazole between
different countries and institutions might explain this discrep-
ancy. Compared with Spanish data applying the old CLSI
breakpoints, we observed a similarly low proportion of
C. glabrata isolates to be non-susceptible to voriconazole (4%
vs. 1.2% in Spain), and the same was true for C. krusei (5% vs.
4%) [30]. However, the application of the new CLSI break-
points signiﬁcantly increased the proportion of non-suscepti-
TABLE 2. Cross- and multiresistant strains according to
breakpoint applied
Strain code Year
Species
identiﬁcation
Fluconazole
MIC mg/L
Voriconazole
MIC mg/L
Cross-resistance
Old CLSI bp (n = 2)
4 2004 Candida albicans 256 16
83 2006 C. albicans 256 8
New CLSI bp (n = 3)
4 2004 C. albicans 256 16
83 2006 C. albicans 256 8
96 2006 Candida tropicalis 32 1
EUCAST bp (n = 9)
4 2004 C. albicans 256 16
33 2006 C. albicans 32 0.5
83 2006 C. albicans 256 8
15 2007 Candida parapsilosis 32 0.25
19 2005 C. tropicalis 8 0.25
40 2005 C. tropicalis 8 0.25
52 2005 C. tropicalis 8 0.5
96 2006 C. tropicalis 32 1
23 2009 C. tropicalis 16 0.5
Multiresistance
Old and new CLSI bp (n = 0)
EUCAST bp (n = 1)a
40 2005 C. tropicalis 8 0.25
bp, breakpoint; CLSI, Clinical and Laboratory Standards Institute; EUCAST,
European Committee on Antimicrobial Susceptibility Testing.
aCaspofungin MIC: 16 mg/L (no EUCAST breakpoint).
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bility for C. krusei from 5% to 36% (for C. glabrata, breakpoint
deﬁnition was dropped by the new CLSI document due to
insufﬁcient evidence). The small number of C. krusei isolates
(n = 22) and the fact that the majority (71%) of non-suscep-
tible isolates had an intermediate susceptibility and not true
resistance might lead to an overestimation of the proportions
of non-susceptible isolates.
Regarding the echinocandins, most Candida isolates were
susceptible to caspofungin when applying the new CLSI break-
points, except for a rather high proportion of C. krusei and some
C. glabratawith an in vitro non-susceptibility rate of 64% and 9%,
respectively. Data published in 2010 analysing CBIs from all over
the world and also applying the new CLSI breakpoints found
lower proportions of non-susceptibility to caspofungin for
C. krusei and C. glabrata (0–9%) [4]. This important difference in
the rate of non-susceptibility to caspofungin is probably due to
the fact that our study includes both truly resistant as well as
intermediate isolates, when applicable, whereas the cited study
considered only truly resistant isolates.
Regarding cross- and multiresistance, overall only nine
(0.8%) isolates were cross-resistant to azoles according to
EUCAST, compared with only three (0.3%) and two (0.2%)
according to the new and old CLSI breakpoints, respectively.
This difference is explained by the lower EUCAST breakpoint
for voriconazole. Only one isolate of C. albicans was multire-
sistant according to the new CLSI breakpoints. The same
isolate was also considered multiresistant according to
EUCAST breakpoints (even if EUCAST has not yet deﬁned
caspofungin breakpoints due to signiﬁcant inter-laboratory
variations in MIC ranges) regarding the very high MIC of
16 mg/L for caspofungin. Although a limited number of
antifungal agents were tested, our data conﬁrm the scarcity
of cross- and multiresistance within the CBIs of Switzerland.
The strengths of this FUNGINOS study are its prospective
and multicentric design with collection of CBIs from a large
number of patients with candidaemia, reﬂecting the nationwide
epidemiology of this life-threatening complication. Further-
more, standardized identiﬁcation and antifungal susceptibility
testing was centralized in the FUNGINOS reference labora-
tory using international standards. A limitation of this study is
that the clinical signiﬁcance of the increased proportions of
non-susceptible C. glabrata and C. krusei could not be analysed
due to the lack of clinical data.
In conclusion, four species (C. albicans, C. glabrata, C. trop-
icalis and C. parapsilosis) represented more than 90% of all
CBIs, with C. albicans remaining the predominant species in
Swiss candidaemia over a 6-year period (2004–2009). In vitro
resistance to ﬂuconazole, voriconazole and caspofungin was
rare among C. albicans, but an increase of non-susceptibility
was observed among C. tropicalis/C. parapsilosis for voriconaz-
ole, among C. parapsilosis for ﬂuconazole and among C. glab-
rata/C. krusei for caspofungin according to EUCAST and new
CLSI breakpoints compared with old CLSI breakpoints. The
recent modiﬁcation of clinical breakpoints, especially EUCAST
breakpoints, has already contributed to a change of treatment
guidelines, in particular regarding C. glabrata.
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